Study design and ethics
This study was designed as a prospective parallel-group randomized controlled trial and conducted at Shengjing Hospital. The investigation was approved by the Institutional Review Board of Shengjing Hospital, China Medical University (approval number 2021PS511K, dated 12/05/2021). The trial was registered with the Chinese Clinical Registry Center (registration No. ChiCTR2200059013, dated 23/04/2022) before patient enrolment. Written informed consent was obtained from all subjects participating in the trial. The trial protocol followed the Declaration of Helsinki. This manuscript adheres to the applicable Consolidated Standards of Reporting Trials (CONSORT) guidelines.